SCHEMBL1945005

SCHEMBL1945005

Cc1ccc(S(=O)(=O)NC(=O)Nc2ccc3c(c2)CCN(C(=O)NS(=O)(=O)c2ccccc2)CC3)cc1

nearest known ligand 0.92

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNA1 Q09470 10/20 0.92
KCNAB1 Q14722 10/20 0.92
LMNA P02545 1/20 0.57
ALDH1A1 P00352 1/20 0.55
HPGD P15428 1/20 0.55
HSD17B10 Q99714 1/20 0.55
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
TP53 P04637 1/20 0.49
CA12 O43570 1/20 0.49
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
CA4 P22748 1/20 0.49
CA6 P23280 1/20 0.49
CA5A P35218 1/20 0.49
CA7 P43166 1/20 0.49
CA9 Q16790 1/20 0.49
CA13 Q8N1Q1 1/20 0.49
CA14 Q9ULX7 1/20 0.49
RAB9A P51151 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1945507 0.96 KCNA1 (1.00) KCNA1KCNAB1LMNAALDH1A1HPGD
SCHEMBL1945684 0.94 KCNA1 (0.80) KCNA1KCNAB1LMNAALDH1A1HPGD
SCHEMBL1944493 0.90 KCNA1 (0.92) KCNA1KCNAB1LMNAALDH1A1HPGD
SCHEMBL1947206 0.90 KCNA1 (1.00) KCNA1KCNAB1LMNAALDH1A1HPGD
SCHEMBL1945192 0.90 KCNA1 (0.92) KCNA1KCNAB1LMNAALDH1A1HPGD
SCHEMBL1947591 0.89 KCNA1 (1.00) KCNA1KCNAB1ALDH1A1HPGDHSD17B10
SCHEMBL1945844 0.89 KCNA1 (0.86) KCNA1KCNAB1LMNAALDH1A1HPGD
SCHEMBL1946654 0.88 KCNA1 (0.84) KCNA1KCNAB1LMNAALDH1A1HPGD
SCHEMBL1946194 0.87 KCNA1 (0.84) KCNA1KCNAB1LMNAALDH1A1HPGD
SCHEMBL1946349 0.87 KCNA1 (0.83) KCNA1KCNAB1LMNAALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110130383-A1 Use of Ion Channel Modulators in the Prophylaxis and Treatment of Inflammatory and Immunological Diseases LECTUS THERAPEUTICS LIMITED (GB) 2011-06-02 US claimed
US-20090318423-A1 Ion Channel Modulators & Uses Thereof LECTUS THERAPEUTICS LIMITED (GB) 2009-12-24 US claimed
US-20110130383-A1 Use of Ion Channel Modulators in the Prophylaxis and Treatment of Inflammatory and Immunological Diseases LECTUS THERAPEUTICS LIMITED (GB) 2011-06-02 US disclosed
US-20090318423-A1 Ion Channel Modulators & Uses Thereof LECTUS THERAPEUTICS LIMITED (GB) 2009-12-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318423-A1 Ion Channel Modulators & Uses Thereof KCNH3, KCNN3, KCNH2 KCNA1 26/4885KCNAB1 40/4885LMNA 3429/4885
US-20110130383-A1 Use of Ion Channel Modulators in the Prophylaxis and Treatment of Inflammatory and Immunological Diseases HCAR2, HCAR1, SCN7A KCNA1 167/4885KCNAB1 98/4885LMNA 3982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.